New β-lactam-β-lactamase inhibitor combinations in clinical development

Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette ChromosomemecTypes

(2012) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

(2012) Elizabeth B. Hirsch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of  -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104)

(2012) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases

(2011) Arnold Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

(2011) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoComparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms

(2011) Catharine C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)

(2011) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14– and CTX-M-15–producing Escherichia coli and Klebsiella pneumoniae

(2011) Emilia Titelman et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria

(2010) Karen Bush et al.   Annual Review of Microbiology

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam  -Lactamase Inhibitor

(2010) T. Stachyra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Three Decades of  -Lactamase Inhibitors

(2010) S. M. Drawz et al.   CLINICAL MICROBIOLOGY REVIEWS